^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

2088 Ktx-120, a Novel Irakimid Degrader of IRAK4 and IMiD Substrates Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX Models

Published date:
11/04/2020
Excerpt:
Importantly, activity was observed in models with a variety of co-mutations that activate the NFkB pathway, including alterations in, CD79B and TNFAIP3…